Clinical trial results:
A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Summary

Results information

Trial information

Trial identification

Additional study identifiers

Sponsors

Paediatric regulatory details

Results analysis stage

General information about the trial

Population of trial subjects

Subjects enrolled per country

Subjects enrolled per age group	

Subject disposition

Recruitment

Pre-assignment

Period 1	

Arms	
Arm title	

Arm title	

Number of subjects in period 1		

Baseline characteristics

Reporting groups	

Reporting group values			

Primary: Overall Survival: Stratified by Histology - Squamous vs. Non-Squamous Tumor Histology

End point values				

Statistical analyses

Statistical analysis title	

Statistical analysis title	

Adverse events

Adverse events information

Dictionary used	
Reporting groups	

Serious adverse events			

Non-serious adverse events			

More information

Substantial protocol amendments (globally)

Date	Amendment

Interruptions (globally)

Limitations and caveats